Is the Hospital Going to Explode on Grey’s Anatomy? – POPSUGAR

411 Shares

Chat with us on Facebook Messenger. Learn what's trending across POPSUGAR.

Not to alarm you or anything, but we may have blown this year's Grey's Anatomy finale wide open. As you might recall, the penultimate episode of the season comes to an explosive end when Stephanie inadvertently causes an oxygen tank to explode. You know, after setting that crazy stalker rapist on fire. While this has us wondering if Stephanie is dead or alive, it could have even graver implications when it comes to the season finale. Back in March, we already got a few details about the episode. Jessica Capshaw told us that it would be "quite explosive," while Chandra Wilson said it would be "big and loud and strong." Are you sensing where we're going with this?

We have a feeling the whole hospital is going to explode. It's not unreasonable. After all, there's already been a huge explosion in one wing. The finale could show the entire cast in crisis, trying desperately to put out fires and save lives. But what if they can't control the fire in time? The episode is called "Ring of Fire." What if the fire overwhelms the hospital while all the other doctors are inside? What if, in the final moments, Grey Sloan Hospital explodes? If you have any doubts, just know this: Shonda Rhimes came up with the idea way back in 2009.

what if at the end of this season of Grey's Anatomy, the hospital just exploded into flames and we don't know who lives or who dies?

shonda rhimes (@shondarhimes) March 9, 2009

See you on Thursday. We'll bring tissues.

Fall TV

Your Guide to Fall's Primetime TV Schedules

by Maggie Pehanick 13 hours ago

Beauty Tips

The $4 and $5 Concealers That Make My Stubborn Under-Eye Circles Disappear

by Sarah Siegel 2 hours ago

Camilla Luddington

Grey's Anatomy's Camilla Luddington Welcomes a Baby Girl

by Kelsie Gibson 4/11

Entertainment Video

Meet Dr. Kari, the Woman Behind Hollywoods Goddess Locs

by M'Ballu Tejan-Sie 1 week ago

Jensen Ackles

Jared Padalecki and Jensen Ackles Have So Much in Common, They're Like Real Brothers

by Shannon Vestal Robson 3 hours ago

Food News

7 Things You Never Knew About Olive Garden, Straight From an Employee

by Erin Cullum 4 hours ago

Grey's Anatomy

5 Connections Between 13 Reasons Why and Grey's Anatomy

by Kelsie Gibson 4/16

Rachel Lindsay

The Bachelorette: Meet the Diverse Group of Men Competing For Rachel's Heart

by Maggie Pehanick 7 hours ago

Heels

Get Your Shine On! These 18 Shoes Have Serious Star Power

by Macy Cate Williams 4 hours ago

Grey's Anatomy

Grey's Anatomy Was Almost Called Something Else and It Was Terrible

by Maggie Pehanick 2 weeks ago

Tim Allen

Even If You Didn't Watch Last Man Standing, You Need to Hear This Drama

by Maggie Pehanick 23 hours ago

Food Video

Let's Get Down to Business to Cook Mulan's Mu Shu Pork

by Megan Lutz 4 days ago

See more here:
Is the Hospital Going to Explode on Grey's Anatomy? - POPSUGAR

A new era for genetic testing, especially in pregnancy – San Francisco Chronicle

A year and a half ago, few health insurers would cover a noninvasive prenatal test which draws blood from a pregnant woman to analyze fetal DNA unless the pregnancy was considered high-risk, which usually meant the woman was over 35.

The test, which screens for chromosomal abnormalities linked to genetic disorders like Down syndrome, seemed less essential for women with average- or low-risk pregnancies.

Today, at least 30 major U.S. insurers including Anthem, Cigna and more than a dozen Blue Cross Blue Shield affiliates nationwide cover the test for average-risk single-gestation pregnancies, expanding access to millions more people.

The turnaround is part of a broader move by insurers to pay for genetic tests and screenings. The technology is advancing quickly, and the cost of many types of tests is plummeting. Not all tests are covered. But increasingly, insurers are willing to cover screenings for genetic mutations linked to breast, colon and prostate cancer.

The trend has sparked concerns about the access insurers could have to the sensitive information such tests reveal.

Photo: Paul Chinn, The Chronicle

Matthew Rabinowitz, founder and CEO of Natera, is seen in a company genetics testing lab in San Carlos on May 4, 2017. Natera projects selling half a million tests this year, he said.

Matthew Rabinowitz, founder and CEO of Natera, is seen in a company genetics testing lab in San Carlos on May 4, 2017. Natera projects selling half a million tests this year, he said.

Paolo Jose calibrates equipment at the Natera genetics testing lab in San Carlos on Thursday, May 4, 2017. Natera Inc makes a non-invasive prenatal test and sells it to OBGYN practices and fertility centers.

Paolo Jose calibrates equipment at the Natera genetics testing lab in San Carlos on Thursday, May 4, 2017. Natera Inc makes a non-invasive prenatal test and sells it to OBGYN practices and fertility centers.

Insurers help make genetic testing widely available

We are seeing more insurance companies cover genetic testing for two reasons: The prices are going down and the value is going up, said Dan Mendelson, president of the Washington consulting firm Avalere Health. The growing coverage of such tests raises some important and extremely socially relevant questions about how the information is used, he added.

The trend is poised to bring a windfall to Bay Area genetic testing firms like Natera Inc., a San Carlos company that makes the noninvasive prenatal test and sells it to obstetrics-gynecology practices and fertility centers. The Natera test, called Panorama, has about 25 percent of the noninvasive prenatal test market share in the U.S. and is the fastest-growing genetic test in the country, according to data compiled by Wells Fargo Securities.

The noninvasive prenatal test is relatively new, coming onto the market in 2011. It is termed noninvasive because the more commonly known procedure to diagnose fetal chromosomal abnormalities, amniocentesis, involves sticking a needle into a pregnant womans abdomen to draw amniotic fluid, which creates a small risk to the fetus. The noninvasive test is not diagnostic, meaning that if it shows a positive result, an expectant mother must still get the result confirmed by amniocentesis. Negative results, though, could reduce the need for invasive procedures.

In December, the Centers for Medicare and Medicaid Services established pricing for aneuploidy and microdeletion testing two chromosomal abnormalities that the prenatal test is designed to detect. Medicaid and many private insurers use the agencys pricing about $800 for one test as a benchmark to set their own prices.

Between 2013 and 2016, Natera sales largely driven by sales of Panorama and Horizon, a genetic-carrier screening more than quintupled from 88,000 to 447,000, according to the company, which went public in 2015 and earned $217 million in revenue last year. Natera expects to sell half a million tests this year, said CEO Matt Rabinowitz.

Coverage is growing beyond the prenatal sphere. More genetic testing for breast, ovarian and colon cancer is being paid for because the information gleaned from the tests is highly predictive, said Lawrence Brody, a senior investigator at the National Human Genome Research Institute, a unit of the National Institutes of Health.

Insurance companies dont want to pay for things that make no health improvements, he said.

Twenty years ago, it cost more than $100 million to sequence the human genome; today, it costs only thousands, according to the National Human Genome Research Institute. Similarly, testing for specific genes is also more accessible.

It used to cost $3,000 to $4,000 to look at just two breast-cancer genes, Brody said. Now it can cost a couple hundred to look at a panel that has 20 genes on it.

Insurance plans are now more likely to cover tests for the gene BRCA1, mutations of which increase the risk of breast cancer, said Mendelson, the health consultant.

That is spilling over to other companies in the genetic-testing space. Over the last nine months, three of the nations largest private insurers Aetna, Humana and UnitedHealthcare have contracted with the San Francisco genetic testing firm Invitae Corp., making the company an in-network provider of diagnostic tests, including BRCA1 and BRCA2, for hereditary breast and ovarian cancer. That is catapulting the number of people potentially covered for these tests from 5 million to 180 million, according to Invitae.

Many genetic tests still are not covered. For example, patients must pay out of pocket for results from the Mountain View firm 23andMe, which sells tests that indicate peoples risk of developing 10 diseases, including Parkinsons, Alzheimers and some blood-clotting disorders.

Where they do cover tests, insurers do not necessarily get access to the results, but a doctor treating a patient may use billing codes that would result in insurers knowing about some diagnoses, according to a spokeswoman for the California Department of Insurance, which regulates insurance companies.

Federal and state laws limit what insurers can do with the information. The federal Genetic Information Nondiscrimination Act of 2008 prohibits insurance companies from discriminating against patients by denying coverage or charging higher premiums based on genetic information. California law goes a step further: It prevents insurers from discriminating against people who carry a gene that may cause a disability in their children.

Cigna does not have access to the test results, said Cigna spokesman Mark Slitt: Thats between patients and their doctors.

A spokesman for Kaiser Permanente said test results are reviewed only by providers and patients and not by the health plan.

A spokeswoman for Blue Shield of California did not directly address whether it saw the test results: As our coverage of genetic tests continues to grow, we go through a deliberate process of making sure the tests are scientifically sound and reliable for our providers and members, she said in an email.

Several of the regions largest insurers, including Kaiser and Blue Shield, said genetic testing can be applied to identify potential medical conditions and improve patients overall health, but they did not provide figures for how many such tests were conducted for their members.

Agreements between insurers and providers are confidential making it difficult to determine how many genetic tests are being done or covered by insurers, said Michael S. Watson, executive director of the American College of Medical Genetics and Genomics, an influential medical association.

Anthem, the first major insurer to expand its coverage of noninvasive prenatal testing to average-risk pregnancies, declined to comment.

Not all genetic testing is useful, medically relevant or accurate, and some experts have cautioned against acting on the results without proper guidance from genetic counselors. Genetics determine just 30 percent of a persons health; the other 70 percent is a combination of behavior, environment and other factors, according to a 2015 report by the Kaiser Family Foundation, which is unrelated to Kaiser Permanente.

You have to be sophisticated to interpret the results, Brody said. We do have a tendency in the U.S. to pile more on sometimes because we can. ... Some genes included three years ago on a breast-cancer test panel have been shown not to influence breast-cancer risk, so we got those taken off. Were learning as we go.

Menlo Park residents Shantanu Rane and Pratibha Gupta took a noninvasive prenatal test last year when Gupta was pregnant with their now-7-month-old daughter. They received a false positive for Turner syndrome, a chromosomal condition in females that can lead to shorter life spans and kidney and heart problems. The couple chose not to do an invasive diagnostic procedure and prepared for the worst. They found out seven months later, when Gupta delivered, that their daughter did not have Turner syndrome, after doctors did a cord blood test analyzing the genetic composition of blood from the umbilical cord.

Rane, who wrote a Medium post about the experience, said he wishes he had known more about how to interpret the results of the test, which showed that a chromosomal abnormality was detected, and that the lab would have been more transparent explaining the result.

There needs to be better education of the patients so they know what theyre going into, said Rane, a researcher in electrical engineering. You have a lot of headache and worry, and at the end you find out things are fine.

Catherine Ho is a San Francisco Chronicle staff writer.

Email: cho@sfchronicle.com Twitter: Cat__Ho

The rest is here:
A new era for genetic testing, especially in pregnancy - San Francisco Chronicle

Nominations open for the PLOS Genetics Research Prize 2017 – PLoS Blogs (blog)

Have you read a 2016 PLOS Genetics Research Article that stood out for you in terms of the strength of its analysis or impact on your field? Maybe you edited or reviewed a manuscript that caught your attention? If so, you may want to nominate it for the PLOS Genetics Research Prize 2017!

Now entering its third year, the prize awards $5,000 to the authors of the winning Research Article, selected by the PLOS Genetics Editors-in-Chief and Senior Editors from a pool of public nominations, based on the criteria of scientific excellence and community impact. Previous winners were Barroso-Batista, Sousa et al. for The First Steps of Adaptation of Escherichia coli to the Gut Are Dominated by Soft Sweeps in 2015, and in 2016, Naranjo, Smith et al. for Dissecting the Genetic Basis of a Complex cis-Regulatory Adaptation.

To tell us which 2016 Research Article you think is worthy of this award, please complete our nomination form. Nominations are open to the public until Friday June 16, 2017 at 11:59 PM ET.

For more information on the Prize, take a look at the Program Page and Program Rules. Questions about the Prize can also be sent to plosgenetics@plos.org.

Featured image credit: December 2016 Issue Image. Immunofluorescent staining of 2-month-old ovarian sections. Image Credit: Meng-Wen Hu

Read more here:
Nominations open for the PLOS Genetics Research Prize 2017 - PLoS Blogs (blog)

5 Things You Need To Know Before Taking an At-Home Genetic Test – NBCNews.com

Genetic testing is now available for over 2,000 conditions from over 500 different laboratories Reuters, file

Prior to April 2017, genetic testing was limited to medical professionals who were testing their patients for certain inherited traits and disorders. With the Food and Drug Administration's approval of the first ever direct-to-consumer test, the company 23andMe can not only sell commercial DNA kits to determine ancestry, but they can test for 500,000 genetic variants to assess for risk of developing any one of 10 diseases. You can do this in the privacy of your home. But should you?

Here are 5 questions to ask before ordering a home genetic testing kit.

Be an informed consumer. Experts recommend seeking professional genetic counseling even before ordering the kit to better understand the implications and limitations of the results. Since the process of developing a disease is much more complicated than just the presence or absence of a certain gene, seeking out the expertise of a genetic professional can aid with putting the results into context based on your family history and medical problems.

Related:

The FDA recognizes the seriousness of this testing, and reports that consumers must first acknowledge that the results may cause anxiety. The opt-in page provides resources to professional medical associations.

In the only commercially available direct-to-consumer test currently available, 23andMe assesses your genetic risk for 10 different diseases.

"The Alzheimer's Association believes you need to think thoroughly before getting a genetic test," says chief science officer of the Alzheimer's Association Maria C. Carrillo, Ph.D. "There are 100s of genes for the Alzheimer's disease. So, it's important for people to know the test is only looking for one gene that has the highest risk for Alzheimer's.

If there are other diseases you are concerned about, speak with your doctor or a genetic counselor who is capable of ordering specialized testing.

No, the current test offered does not have the capability to diagnose you with a certain disease. It can only inform you of your genetic risk, but not overall risk. Keep in mind DNA is not the sole determinant of disease. There are also gene variations, family history, lifestyle choices, and the environmental factors to consider in how genes are expressed. Just because someone has a genetic risk does not mean they will go on to develop the disease. In cases of sufficient scientific evidence, a genetic report will even be able to quantify a risk percentage. For example, having two copies of a certain gene variant raises lifetime risk of developing Alzheimer's disease as high as 87 percent.

Related:

Privacy continues to be a top concern as technology rapidly advances. Transparency and easy of accessibility are what companies are considering when making their privacy policies. According to the National Society of Genetic Counselors, before sending in your DNA, it is important to ask:

Different state and federal laws exist, such as the Genetic Information Nondiscrimination Act, which prohibits employers from discriminating based on genetic information. The Affordable Care Act also offered protections against health insurance companies from discriminating based on genetic testing results.

However, as health care legislature continues to evolve, it will be imperative to keep an eye on what new policies come forth.

Mary Freivogel, president of the National Society of Genetic Counselors Board of Directors, notes that there are currently no federal laws that exist relating to protections for life insurance, long term care insurance, or disability insurance.

Just as experts recommend seeking advice from a genetic counselor prior to testing, it is probably more important to have a professional weigh in once the results are back. They can help you interpret the implications of your genetic risk, understand what you can do to prevent or monitor for early signs of the disease, and how you should discuss your results with relatives who have similar DNA.

"It goes beyond the science and genetics and one should think about the societal and family implications," says Carrillo. "Talk to the genetic counselors before and after taking a genetic test. It is important understand the results since it can have implications for you and your family."

If you are considering sending off you spit here are additional resources about genetic testing to help inform your decision.

Parminder Deo is an associate producer for NBC News. Dr. Jacqueline Paulis, is an emergency medicine resident physician in New York City and a medical fellow for NBC News.

More:
5 Things You Need To Know Before Taking an At-Home Genetic Test - NBCNews.com

Harvard’s Pamela Silver recalls journey from Silicon Valley to synthetic biology – Harvard Gazette

Life stories from Annette Gordon-Reed, Martin Karplus, Joseph Nye, E.O. Wilson, and many more, in the Experience series.

In 1960s Silicon Valley Pamela Silver came of age part math nerd, part rebel, absorbing the spirit of both time and place. Think space race. Think Grateful Dead.

She set out on her scientific career without a plan, propelled by an aptitude for math, an interest in science, and a love of the sometimes frenzied life of the laboratory. That love fueled groundbreaking work on how proteins make their way from the cytoplasm of a cell into the nucleus, a process called nuclear localization. Decades and many discoveries later, the same passion helped establish her as a leader in the fledgling field of synthetic biology.

Silver was recently named a fellow of the American Academy of Arts and Sciences. She is the Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology.

Q: Lets start at the beginning. You grew up in Atherton, Calif., in Silicon Valley?

A: [My parents] were both psychotherapists, and it made for an interesting childhood. I think they must have met here [in Boston] and then they moved to the Bay Area probably right after the war, late 40s, early 50s. And my father became one of the founders of the Palo Alto Medical Clinic; it was one of the first group practices, sort of soup-to-nuts. [He] was also on the Stanford faculty. They moved to California right at the beginning of the rapid growth of Silicon Valley. We lived in Atherton before it was the richest town in the world. It was kind of cool, these old estates, built by James Flood and his children big mansions and big land. They were just starting to subdivide it. Our house was one of the first ranch-style homes. It was already kind of upper class, but I didnt realize that at the time; it was just where we lived.

Q: You never do when youre a kid. You just grow up in your surroundings.

A: The roads were still dirt. The Flood granddaughters still lived there and had horses, so we could walk around and feed the horses. It all seemed very idyllic to me, I guess if I think back on it, which I do more and more. My parents were very high-level thinkers and very intelligent. That obviously set the tone in our household, maybe a little overdoing it. My sister was actually 10 years older, so it was more like I was an only child.

Q: Is your sister your only sibling?

A: Yes. My parents did get divorced. We were not a tightknit family but more highly dysfunctional. And in retrospect that was OK in terms of my own independence and things like that.

At that time in Silicon Valley, everything was very science-oriented. How do we promote science in schools it was all about the space race and stuff like that. I apparently had precocious math ability. Some on my fathers side of the family had an inclination to mathematics. He nurtured this. He taught me how to play Go when I was 6. Chess, maybe, but Go? Really?

I won an IBM math contest when I was in junior high, but nobody was pushing me. My parents were so preoccupied with themselves, they just wanted to make sure that I didnt do anything bad.

Q: I read that you got a slide rule as a prize?

A: Yeah, that was the prize. What a hoot. It wasnt just any slide rule. My slide rule had a beveled edge, so the slider thing was here and you could still use it as a straight edge. What an amazing slide rule. Ive never been able to find one like it. I also loved homework. I would beg the teachers in elementary school to give me homework, partly because I think it was a way to get lost from the family dysfunction and also it was just interesting.

Q: What about your early schools?

A: I went to the public high school, which was nearby, for a year. Then my parents sort of decided that I wasnt getting the right education. They sent me to a local all-girls high school called Castilleja. Its one of the few all-girls high schools left. It didnt seem to emphasize science very much. The times were very disruptive. There was a lot of protest and the Vietnam War, and there you are in the all-girls school. It was a bit odd.

Q: You said it wasnt heavy on science. Was your interest in

A: My interest was independence. I have to say I was kind of a wild kid in high school. Lets be honest, there was a fair amount of recreational drug-taking and going to the Fillmore Auditorium I was heavily into the music of the times. The Grateful Dead were still kind of a local band and we were big fans it was a big part of the local culture. Bob Weir grew up nearby, and they used to practice locally. Even when we were kids, we would go listen to them. They would play at local parks and pizza parlors.

The great thing about my school is that the teachers took a personal interest in me. I had one teacher that thought I was a good writer. No idea why. The Palo Alto Times the school was in Palo Alto would have a student from each school write columns, and so she assigned me to be the reporter for Castilleja. So I really got into that. Then there was this whole culture around personal computers and electronic hacking. There were so many wacky things going on, and even as teenagers we were very much part of that. Not clear how the parents felt about it.

Q: What about college?

Castilleja was very much a college prep school. I applied to Stanford and Yale, but my real top choice was UC Santa Cruz, which is where I ended up going. I knew from the start that I wanted to do science, so the other good thing was that there werent very many course requirements or grades. I took as many advanced placement tests as possible, so I wouldnt have to take anything but science classes, which probably made my whole undergraduate experience very warped. I started as a math major, maybe, then went to physics, and then ended up in chemistry. One thing I wanted to do, which Santa Cruz was very big on, was independent research, and so as fast as possible I just wanted to get into that, and I did.

Q: Where did your initial interest in science come from?

A: I would say its a combination of this uber-intellectual family life and also the school system, for sure. There were science contests and endless science projects, and my father fed that a little bit. I remember, in first grade, he brought a dissected cat to the class, because he was an M.D. Hed take me to the hospital all the time. A lot of our family friends were somehow connected to either the medical or engineering [fields]. My father used to play poker with [Nobel Prize-winning chemist] Linus Pauling, and one of my first job interviews in high school was at his institute. Other fathers gave me early programmable personal calculators for homework.

Q: So, youre in college, and youre wending your way from math to physics to chemistry. How did that go?

A: The math part I dont remember much about. Physics was transient also. What I realized about myself was that I wanted to do experiments. So I think I ended up in chemistry because of the opportunity to do experiments. Im sure it was a product of people I met and knew and things like that teachers but also I always was kind of a rebel. Everyone was majoring in psychology, that was the thing. There was just no way I was going to do what everyone else did.

Q: No temptation, given your parents background?

A: Absolutely none. Zero. Med school off the table. Forget it. College was meeting up with just crazily interesting people. And Santa Cruz was just idyllic. Youd go off in the woods and the trees and surfing oh, and sailing. Big deal, sailing. Probably the one thing that I got out of that was being on the sailing team and having something organized in my life. So that was different and fun.

Our whole goal was to make the engineering of biology faster, cheaper, and more predictable. Lets say we succeed. So then what? Do we have the perfect planet? Is everything wonderful? Is there misuse? Im thinking about things I dont know the answer to.

Q: Are you still a sailor?

A: Yeah, its [in the picture] right behind you. Thats my boat.

Mostly I worked in the lab a lot. I liked the lab culture. I liked the all-night thing and feeling like you belonged and you were working on something. I really liked that part of it. I just characterize my life as not having a plan. And people say to me: But youre at Harvard, howd that happen? It just kind of happened. Im not saying that was a good thing or a bad thing, but I do compare it to these kids now who start out so early with a plan. I am glad I had time to explore and be kind of a dreamer.

So college is ending. I heard about this graduate school thing, and maybe I should apply. Id heard of two chemistry programs that I thought would be, for some reason, good. One was Berkeley and one was Harvard. Those were my only two grad school applications. I remember somehow deciding that I didnt want to go to grad school, though. I forget why. My father had died. I just didnt feel right. I had no money, and so I decided, maybe Ill just get a job. It was all complicated with boyfriends and husbands and lots of stuff. I did get a job at a startup chemical company, literally in Silicon Valley. It was across the street from Hewlett-Packard, really in the thick of it.

Q: So how did you end up going back to graduate school?

A: With my then-spouse, I moved to Los Angeles. The short story is thats how I ended up going to UCLA for grad school. Id actually spent an extra year at Santa Cruz doing this protein structure work, so I bargained with UCLA. If I could pass the equivalent of their qualifying exam, could I not take any classes and therefore finish my Ph.D. as fast as possible? I passed it, and so I got my Ph.D. in three years. I had a very supportive adviser who said you should just get your Ph.D. really fast. It was a good experience.

Q: How was choosing Harvard for a postdoc different from not choosing it for grad school?

A: Maybe there was finally an element of careerism starting to emerge. All these guys at UCLA were super young hotshots, and they had all come from Stanford and Harvard. So there was probably an element of hey, I can do that.

At the same time, my adviser kept trying to push me, which just was perfect for me. He kept saying, try to do something where you set up your own research program. I did formulate a question in my mind of what I thought I wanted to solve. That was the question of how do things proteins and RNAs move between the nucleus and the cytoplasm? I had some hypotheses about this, so I approached a couple of faculty here.

One was well known for letting people come to do whatever they wanted, so I went there. But I spent the summer before at Cold Spring Harbor. I went there to take the yeast course, which was a big deal then. That was just a total eye-opener.

Q: Learning how to manage and use yeast as an experimental organism, essentially?

A: Yes, but it was also about learning how to think as a geneticist, and it was just transformative for me. In many ways being at Cold Spring Harbor was amazing. Being in this community of scientists where it had that kind of 24-hour science-is-the-big-thing, interesting people to talk to left and right. Id never seen anything like it. Youre just kind of away from all your responsibilities. It was just very magical and crazy, and I thought, jeez, this is how it should be.

So when I got back to Boston, I started working in the lab Id chosen. And I met people in Mark Ptashnes lab, which was kind of a happening place. There was a lot of energy.

I realized that I was initially not in the right lab nothing wrong with it, it just wasnt right for me. So I went to Mark, and I said, I have this idea, and Ive thought more about it. I think I could test it better using yeast. And he was starting up this yeast group. So I joined Marks lab, and it was an amazing experience. The people there were just insanely smart. I mean, there were ups and downs, for sure, and some of those people could fight like dogs. It was either politics or science. It was just a crazily intense environment and I solved my problem. I discovered how proteins have a sequence that targets them into the nucleus, and that was one of the first examples of that. And I really did it on my own.

[At the end of the postdoc] everyone else seemed to have a plan. I said, hey, if this whole nuclear localization thing doesnt work out, Ill do something else. I did not have the Im-going-to-be-a-professor-for-sure mentality at all. I remember picking a couple schools that I thought I might actually go to if they offered me jobs, places that had openings. It was a very short list. One was Harvard. And one was Yale. One was Princeton. And one was Cornell.

I had interviews everywhere. I did not think about gender bias back then. I really did not. There were times I realized in college I was the only woman in the class. I just never felt anything [sexist] until I went on those job interviews and there were almost no women faculty mostly dinners with all guys. Then I had an offer at Princeton. And then at Yale. Princeton was sort of: Were growing, were new. And I thought, well, that sounds interesting. And I went to Princeton but did not stay for long.

Q: You went to Dana-Farber Cancer Institute and were there for a while, right?

A: Yeah. I was hired in BCMP [Biological Chemistry and Molecular Pharmacology], and Chris Walsh was the chair. And he essentially saved my scientific life. I always say they took a risk on me. Many people said something like, Oh my God, youre going to go to Harvard? Theyre so mean. Its going to be horrible. It was the antithesis of all those things super-supportive and they wanted me.

Q: So you were here as an associate professor?

A: Based at Dana-Farber. My full appointment was in BCMP. It was back in the old days, when getting tenure took forever. The agreement was that when I was hired, they would start the process. And back then, the process sometimes took two to three years. So I had to sweat it a bit, but I had good friends there and good support. Ive been blessed with regard to funding for my research, so far. I was worried being at Dana-Farber would be odd for me as a basic scientist, but it turned out it was fabulous. I was worried I wouldnt get grad students. That turned out not to be true got great students, great postdocs. And I continued to work on cell biology combined with molecular biology, and then it expanded into what you loosely might call systems biology.

And my work had some cancer overtones to it in that we did discover we did a small molecule screen where we discovered small molecules where, in principle, we could decipher the mechanism by which they would revert cancer cells away from cancer.

Q: How did you transition from Dana-Farber to what was then the new Department of Systems Biology at Harvard Medical School?

A: My own research was transitioning. I was taking a more systems-wide view of the cell biological problems I was working on. And also I was starting to feel like it was a time in my life where I was looking to change.

It was a really good time for Dana-Farber. They were starting to get a handle on making targeted drugs for cancer, the kinase inhibitors. And I felt good about Dana-Farber, that they were going in a good direction, that they were closer to real cancer cures. But I wasnt sure that my work was still a good fit. It had been so I mean that in a positive way.

The other thing that happened that was probably more consequential was that my now-husband, Jeff Way, who works here at the Wyss Institute, was helping a friend of ours start a new institute in Berkeley. He met a young postdoc there named Drew Endy and they became good friends. Drew had come from civil engineering, I think, and [he was] thinking about where biology should go. And then he came here this was in the early 2000s, late 1990s and started this group at MIT. It was bioengineers, computer scientists, and included me as the token real biologist. And that became the Synthetic Biology Working Group.

It was nearby, so I could go over there a lot. I became pretty engaged in that. Then, simultaneously, Marc Kirschner [of Harvard] was starting this new department [of systems biology]. Marc asked me if I wanted to be part of this department.

Q: And this was in around 2004, right?

A: Right. It was fun to be around new people, new ideas, and also I was given the charge of starting the new grad program.

Q: Lets talk about the grad program and your thoughts on graduate education.

A: Ive had a ton of grad students, and I watched them matriculate and turn into scientists. Id been thinking a lot about it and what that meant, and also this engagement with MIT was giving me a different perspective. One idea was it shouldnt be that you come to grad school and just take a bunch of classes. You come to grad school to do research. They should engage in research soon and they would get custom mentoring. Also, we tried to attract students from a diversity of areas. They could come from computer science or math. So they didnt necessarily have to have a biology background.

The other thing I encouraged was collaborative projects, so you could have, for example, two advisers. A lot of students took us up on that. That would increase collaboration amongst the faculty through the students.

It goes to the idea that the students are empowered and theyre helping define their education. It was about getting a mix of faculty across the University from different disciplines, not just the Medical School. Have a big umbrella. I liked that component of it. We got a significant number of applicants, and they were just amazing; they were some of the top students in the country. And then it stayed that way, and we got these interesting, quirky students. Im not running it anymore. Its still a great program.

Q: During this period, you were starting to focus more on synthetic biology, right?

A: Right.

Q: So tell me a little bit about that. You were at the meetings at MIT. Were you coming to understand the potential of looking at biology as modular, that it could be engineered in a rational way once you figured it all out?

A: The modularity of biology was something that resonated for me, because it was the essence of much of my work in molecular biology. I had done things like take parts of proteins and fuse them to other proteins and show they could move to the nucleus in the cell. So thats one essence of modularity. I was primed to think about it that way. I dont know if I called it synthetic biology or anything, but it was very much in my wheelhouse.

Q: Lets talk about your lab. What do you consider milestones?

A: Well, the first one was programming yeast to sense radiation. You can build sensors, but we wanted to build cells that not only sensed, but remembered. That was one of our first successes: building predictable circuits in yeast.

Q: How do you get a cell to remember?

A: There are a lot of different ways. Our way was to use transcriptional control, which is regulating how genes are made. One theme of our research is to draw from what we know about nature and try to apply that to practical problems. What nature tends to do with transcription is to use different kinds of feedback control that can either be positive or negative. So we took advantage of that. If you have a signal, instead of just having one burst, [we engineered it to] keep itself going, so it has this continuous feedback control. Thats a process used by nature that we deployed in our work.

Q: So exposure to radiation would trigger a process that

A: Yes. Imagine it triggers a pulse and something happens, and then that promotes a more sustained response over time.

Q: And that sustained response is the memory?

A: We call that the memory, yes. Memory of course means a lot of things to a lot of people, especially in neurobiology. So were using the term memory in a loose way here.

Q: And without this, the cell would respond and then stop?

A: And stop, yes.

Q: So youd be able to look at it and say, since this process is ongoing, something happened in

A: That it happened sometime in the past. My overall dream, which I think were close to achieving, is not only would something happen in the past, but a cell then could count and tell you when it happened, so it would be a true computer. And it would tell you when it happened and then ultimately do something. That doing of something, hopefully, could be something practical, like emit a signal that tells you there are poisonous chemicals somewhere or that theres a pathogen, or produce a therapeutic on-demand at the right time. We havent gotten there, but, at the time of me getting involved in synthetic biology, that was the overarching dream. Now weve taken a lot of different side paths.

We have this paper coming out in a few weeks about sensing inflammation in the gut. That, of course, is a huge problem in general. Theres no good treatment and its a chronic disease. Many people suffer from it. So we can create intestinal bacteria that will report on inflammation. Now the question is, can we get them to make a therapeutic for it? Thats one of the examples of the dream getting close to reality.

Q: Another project youve worked on is the bionic leaf.

A: Its super exciting. There are just so many opportunities here at Harvard, sometimes you look back and you say, oh my God, this thing happened. I was working on cyanobacteria, which are one of the simplest organisms that do photosynthesis, and we had engineered them to make hydrogen. We were believers in the hydrogen economy, which kind of didnt turn out so well. It might come back someday.

I got invited to be part of the Harvard University Center for the Environment, and Dan Schrag, the director, introduced me to Dan Nocera at the holiday party. Dan Nocera he had just moved [to Harvard], and he said something like, Ive been trying to meet you. Ive got this artificial leaf. It makes hydrogen. And I responded with, Ive got these bacteria, and theyll eat hydrogen and fix CO2. It was like two synergistic personalities; it just clicked.

Q: Looking ahead in synthetic biology 10 years from now what do you think will be most important?

A: In the perfect world, I would say on-demand drugs would be a big deal, whether that be protein-based drugs, cell-based drugs, or chemicals. For example, a friend of mine who is a professor at Stanford has made yeast that will make opiates. Think about the consequences of that. One is economic and the other is to make designer opiates that get rid of some of the bad things about them. I think thats just an example of the power of biology to make things weve never seen before.

We are at a tipping point around DNA synthesis. Its not yet cheap enough where a grad student could say, Im going to build a whole new organism. We need another kind of technological leap.

Our whole goal was to make the engineering of biology faster, cheaper, and more predictable. Lets say we succeed. So then what? Do we have the perfect planet? Is everything wonderful? Is there misuse? Im thinking about things I dont know the answer to. How do you find the genetically engineered organisms [released into the environment]? How do you respond quickly to a pandemic? These are things I think we are poised to do well. Can we make a vaccine in a day? Can we figure out what a pandemic is in a few hours? That really fits the bill of faster, cheaper.

How do we marry the coming firestorm of AI with synthetic biology? There was a time when young people wanted to work on molecular biology. That was the cool thing. AI is the cool thing now. Hundreds of undergrads at MIT want to take Intro AI. So we have to capture that imagination and meld it with synthetic biology.

Q: Do you look at young women in science today and think about how things are either different or the same as when you were coming up?

A: There are still a lot of males in charge and, as you get higher up the food chain, you start to notice different things. There are still times Im the only woman in the room. I have my one activism thing, where if I see meetings with no women speakers, I write a letter. I have some things that I call out, like science advisory boards with no women. So I make a pest of myself every now and then, but so do a lot of other people.

But about the trainees that is something I think were all worried about. Its a complicated problem. It feels like its harder to get women applicants and have them stick with it. I try to encourage the women in my own group. But at the same time, they have to make choices that make them happy. There just still arent a lot of women at the top. How much impact does it have if youre a younger woman and you dont see women in [leadership]?

If Harvard holds a symposium, it should never be all male. Any topic theres no reason. These, to me, are cheap, simple fixes. You should never have posters for conferences that have all males. That costs you almost no money. So I think there are lots of things you can do that dont require major investments that send signals that are positive.

Q: They say that science is at least partly about failure and learning from failure. Do you have advice on how you deal with failure?

A: Its very hard to say to someone, Look, its just not working. So I try to do it early and then say, Lets move on. Why dont you work on this thing that is working for a while so you can feel what its like to have something work, and then maybe thatll get you a paper or chapter in your thesis. Then you can go back to something riskier.

But at the same time, I like to encourage people to be risk takers, because if you dont take risks, youre not going to get anywhere. So there has to be some balance. I will say its the thing I most lose sleep over. Forget not getting grants and all that. Its the people you worry about you want everyone to succeed. At my stage, this is not about me anymore. Its about them.

Read the original:
Harvard's Pamela Silver recalls journey from Silicon Valley to synthetic biology - Harvard Gazette

Health and reproductive biology: a research record of paradigm-shifting discoveries – Nevada Today

At the moment of reproductive fertilization, much of a person's health perspective is determined by the genetic and epigenetic information contained within the sperm and egg. This research finding has changed our understanding of health and disease.

Wei Yan, foundation professor of physiology and cell biology at the University of Nevada, Reno School of Medicine, was one of the first to validate this important finding. In recognition of his distinguished research record and paradigm-shifting discoveries, Yan, who holds a medical degree and a PhD, has received the University's 2017 Outstanding Researcher Award.

Yan's research on the genetic and epigenetic regulation of human and animal reproduction is internationally recognized, and his research has been continuously supported by grants from the National Institutes of Health and various foundations.

Factors such as nutrition, lifestyle, or environmental exposures all impact health. But Yan's research indicates that the quality of the gametes (sperm and eggs) has a huge impact on the health perspective of the offspring. His research has discovered that environmental insults can lead to genetic and epigenetic alterations in the gametes, which not only compromise fertility, but also predispose the offspring to many common diseases, which sometimes can even be inherited across multiple generations.

"We were among the first putting forward this provocative idea that may explain the development of many common diseases," Yan said. "Researchers and science no longer look for one generation's impact on disease development."

A significant discovery by Yan's team is the quality of sperm in determining the overall health of the offspring. It was once thought sperm only deliver the father's DNA into the egg, but Yan's research has shown that, in addition to genetic information, sperm also carry over a large amount of epigenetic information during fertilization.

"They carry not only the DNA blueprint but also the regulators of DNA," Yan said of the role of sperm. "This finding has allowed us to link sperm quality to disease development in the offspring."

The study of sperm in Yan's lab has also contributed to new ideas and approaches to reproductive health, including advances toward the development of non-hormonal, male contraceptives.

"Dr. Yan is an outstanding scientist of international reputation whose expertise in epigenetics and reproductive medicine has led to discoveries of great importance to human health," Tom Schwenk, dean of the University of Nevada, Reno School of Medicine. said.

Considering his contributions, it is all the more incredible to think his career in research almost didn't happen.

As Yan worked toward his medical degree from China Medical University, which he earned in 1990, he found himself drawn to laboratory settings rather than clinical practices. He pursued a fellowship in forensic pathology, and the timing of his entry into this medical and scientific arena coincided with the expanding application of new DNA technologies.

"I saw the birth and emergence of DNA testing, and my background in medicine and pathology positioned me to study this new area," he said.

Yan became the first person in China to develop and use these technologies to solve criminal cases. His time as a coroner with the Institute of Forensic Sciences for China's Liaoning Province was, as he said, "real-world CSI."

At crime scenes the most common finding is hair - not blood or bodily fluids - and because the hair shaft is enriched in mitochondrial DNA, the application of DNA testing is very effective. Yan's application of the science resulted in a dramatic increase in solved criminal cases, particularly sexual assault cases, and he was called upon by agencies across the country looking to apply the science to their investigations.

His family was proud to see Yan achieve this early-career success, but Yan was ready to head in a new direction. He quit his job to embark on a career in research and explore his newfound passion: "Doing something new, exploring something new, always looking at new questions."

He earned his PhD in physiology in 2000 from the University of Turku in Finland where he was part of an internationally renowned research lab in the study of endocrinology and reproduction science. He later completed a postdoctoral fellowship in the Department of Pathology at Baylor College of Medicine in Houston, Texas.

Related Academic Programs

Foundation Professor and Chair of the Department of Physiology and Cell Biology Kenton Sanders recruited Yan because of his extraordinary skills and ideas regarding reproductive biology, transgenics and molecular biology.

"He rapidly developed a productive laboratory and has consistently been one of the most productive and well-funded members of the faculty," Sanders wrote in his nomination of Yan for the Outstanding Researcher Award. "Wei has made significant contributions in the field of reproductive biology ... and has recently developed ideas and new techniques for the study of epigenetics and has worked hard on contraceptive development."

Yan has published more than 110 peer-reviewed articles with more than 5,400 citations. He holds three patents, and he has received numerous awards, including the 2009 Nevada Regents' Rising Researcher Award, the 2009 Society for the Study of Reproduction Young Investigator Award, the 2012 American Society of Andrology Young Andrologist Award and the 2013 Nevada Healthcare Hero Award for Research and Technology. In 2016, Yan was named a University of Nevada, Reno Foundation Professor, the highest honor the University bestows upon its faculty.

Yan recently received a prestigious appointment to serve as editor-in-chief of the journal Biology of Reproduction as of July 2017.

Looking back at his career, Yan places great value on the role of mentorship.

"I came here as a young assistant professor and started to look for role models," Yan said. "I sought out high-achieving scientists to learn from."

He learned a great deal from Sanders, who Yan describes as visionary and always watching where the science is going.

"I'm lucky to be in UNR Med, surrounded by top-tier scientists," Yan said. "I appreciate the collegiality in this relatively small research community, especially the support from the department chair and the dean."

He appreciates the importance of giving back and mentoring others. "My goal is to create a competitive and supportive environment, to have enthusiastic graduate students and post-doctoral fellows and contribute to their development, to make many more discoveries beneficial to human health."

"He is an expert mentor who has built strong and productive research teams," Schwenk said. "The School of Medicine is proud that Dr. Yan has been selected to join a long line of scientists and investigators recognized as outstanding researchers at UNR."

Yan formally received the 2017 Outstanding Researcher Award and a $5,000 award grant at the University's Honor the Best Ceremony on May 16. For more information about this and other awards presented through Research & Innovation at the University, visit unr.edu/research-and-innovation/support-opportunities/awards.

See original here:
Health and reproductive biology: a research record of paradigm-shifting discoveries - Nevada Today

Dragonfly Therapeutics Announces Head of Biology – Canada NewsWire (press release)

Dragonfly announces that Dr. Ann Cheung will become its Head of Biology, leading critical development of the company's novel Natural Killer cell-based immunotherapies.

CAMBRIDGE, Mass., May 16, 2017 /CNW/ --Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Dr. Ann Cheung will become its Head of Biology, directing key immuno-oncology functions for the development of its novel Natural Killer ("NK") cell-based therapies.

"Ann is an outstanding scientist," said Dragonfly co-founder and head of the Koch Institute for Integrative Cancer Research at MIT, Dr. Tyler Jacks. "After working with her for six years in MIT labs earlier in her career, I know that she will bring immense creativity, innovation, experience and drive to her important role as Dragonfly's Head of Biology.

As Dragonfly's Head of Biology, Dr. Cheung manages all immune-oncology functions for the development of the company's proprietary NK cell engagers, directing research into NK cell biology and mechanism of action. She works closely with the Head of Biologics, Dr. Asya Grinberg.

At the Jacks lab, Ann studied the interface of between lung tumors and anti-cancer T cells, and initiated the group's forays into cancer immunology. Ann's postdoctoral work was at Caltech, and included a collaboration with Drs. Antoni Ribas and Nobel Laureate David Baltimore to assess T cell multi-functionality in a clinical trial using engineered T cells for immunotherapy in advanced melanoma patients. Ann received her undergraduate degree from Brown University with a concentration in Biochemistry and Molecular Biology, and received her Ph-D from the MIT Department of Biology.

About DragonflyDragonfly Therapeutics harnesses its novel TriNKET technology to develop drugs that leverage the power of the innate immune system to provide breakthrough cancer treatments for patients.

For more information visit: http://www.dragonflytx.com, https://www.facebook.com/dragonflytherapeutics/, https://twitter.com/dragonflytx

Media Contact: Maura McCarthy 617-588-0086 x702 maura@dragonflytx.com

SOURCE Dragonfly Therapeutics, Inc.

See the original post here:
Dragonfly Therapeutics Announces Head of Biology - Canada NewsWire (press release)

ABC fall 2017 lineup: ‘Grey’s Anatomy’ spinoff, ‘Good Doctor,’ more – Newsday

ABC will spin off series from three franchises next season Greys Anatomy, The Bachelor and Dancing With the Stars and add yet another Marvel-based drama, the network announced Tuesday.

The Greys spinoff will be set in a Seattle firehouse, with characters introduced on the flagship series next season. In addition, The Bachelor Winter Games will cast past contestants in a series with winter-themed athletic challenges including the toughest sport of all, love.

Then this: Dancing With the Stars Junior will pair celebrity kids and kids of celebrities with professional junior ballroom dancers. No airdates set, but the reality series will premiere next year.

ABC executives also said the network will air a live comedy special produced by Jimmy Kimmel and Justin Theroux featuring comics reading scripts from classic sitcoms.

Heres the fall lineup:

Monday: Dancing With the Stars (8); The Good Doctor (10), with Freddie Highmore as a surgeon with autism and savant syndrome.

Tuesday: The Middle (8); Fresh Off the Boat (8:30); black-ish (9); The Mayor (9:30), about a rapper (Brandon Micheal Hall) who becomes mayor (its produced by Daveed Diggs of Hamilton); The Gospel of Kevin (10), with Jason Ritter and JoAnna Garcia Swisher, about a guy on a mission to save the world.

Wednesday: The Goldbergs (8); Speechless (8:30); Modern Family (9); American Housewife (9:30); Designated Survivor (10).

Thursday: Greys Anatomy (8); Scandal (9); How to Get Away With Murder (10).

Friday: Once Upon a Time (8); Marvels Inhumans (9), about Black Bolt (Anson Mount) he with the very loud voice and his family of Inhumans; 20/20 (10).

Saturday: College football

Sunday: Americas Funniest Home Videos (7); To Tell the Truth (8); Shark Tank (9); Ten Days in the Valley (10), with Kyra Sedgwick as a news producer whose child goes missing.

Read this article:
ABC fall 2017 lineup: 'Grey's Anatomy' spinoff, 'Good Doctor,' more - Newsday

StaTuesday: Anatomy of Twins’ home run streak – FOXSports.com

The Minnesota Twins might not be baseballs most powerful team, but they might be the most efficient.

The Twins are tied for 21st in the majors with 40 home runs in their 32 games. However, Minnesota is bunching those homers together.

In those 32 games, the Twins have hit at least one home run in 24 of them (75 percent). In addition, Minnesota is currently on a streak of hitting a home run in a 15 consecutive games, which is one shy of the club record set in 1979.

Minnesota had multiple homer six times during that 79 run; this year, just four times in the 15 games.

Before this season, no Twins team had a streak as long as 12 games since 2002.

The 1979 team had eight player home during their 16-game streak. Catcher Butch Wynegar his five of his seven homers that season in that span while FOX Sports North announcer Roy Smalley smashed six.

This years Twins team has seen 10 different players homer during the 15-game streak, including one by a player no longer with the franchise. Joe Mauers walk-off winner on May 5 against Boston was the only homer that game.

If this years Minnesota team is going to tie the franchise record for consecutive games with a home run, itll have to avoid a bit of a coincidence. That streak in 1979 just happened to end at home and wait for it on May 16. (We also will hate to point out that Colorados starter Tuesday is rookie Kyle Freeland, who has allowed just one homer in 40 innings.)

Dave Heller is the author of Ken Williams: A Slugger in Ruths Shadow, Facing Ted Williams Players From the Golden Age of Baseball Recall the Greatest Hitter Who Ever Lived and As Good As It Got: The 1944 St. Louis Browns

Go here to see the original:
StaTuesday: Anatomy of Twins' home run streak - FOXSports.com

Hanover High artist inspired by anatomy class – Wicked Local Hanover

Adam Silva adsilva@wickedlocal.com @AdamSMariner

Even though 2,700students won the same type of award, Tori Miller is in pretty exclusive company when you consider 330,000 students from around the world entered the competition.

The Hanover High School seniors colored pencil piece "Blackout"was submitted to the Scholastic Art and Writing Awards, also known as the Globe Show and placed in the silver medal category amid thousands of entries.

Surprisingly, Miller's work was created for an anatomy class, not an art class.

We were doing a project on how chemicals affect the body, so we got to pick the topic, said Miller. Im into makeup, so part of it was to create a propaganda poster, so I was just looking for references to put on my poster. I saw the womans photo on Tumblr and I thought it was a beautiful photo to put on a poster. It was a really quick drawing and it wasnt until this year that I touched it again. I didnt add the blue background until I touched it again for this piece.

Hanover High art teacher David Crawford suggests all advanced placement art students submit pieces to the show and Miller added the piece to her portfolio for the class. Several teachers have gone out of their way to commend Miller on her success and to heap praise for her talent.

Not to take anything away from Tori as an individual, but I want to emphasize the fact that the support of her friends is a big part of the success of all of them, said Crawford. She represents the best that Hanover has to offer. Im very glad that she was selected for this and not just for her, but for Hanover itself. Its the best that these kids can do.

Despite her clear talent for art, Miller's love of four-legged creatures is leading her to a career as an animal care specialist. While it sounds the same as veterinary medicine, Miller contends that its different.

The schools she is looking at are Becker College in Worcester and North Shore Community College in Danvers, two of the only colleges in the area that offer the major.

Im still waiting to hear back from them since I applied and I guess it went into their spam mail, she said, with a nervous laugh. Hopefully, if I hear back from them, Ill start as soon as I can.

Follow Adam Silva on Twitter @AdamSMariner.

Here is the original post:
Hanover High artist inspired by anatomy class - Wicked Local Hanover